# What changed when an IVF trial added triptorelin to hCG?

- Article ID: research-401
- Product: Triptorelin GnRH (triptorelin-gnrh-502)
- Canonical page: https://heritagebiolabs.com/research-library/articles/401-what-changed-when-an-ivf-trial-added-triptorelin-to-hcg
- Product collection: https://heritagebiolabs.com/research-library/products/triptorelin-gnrh
- Product page: https://heritagebiolabs.com/product/triptorelin-gnrh-502
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are small strings of amino acids held together by peptide bonds. Some can briefly call an endocrine gland into action. Triptorelin acetate contains a synthetic ten-amino-acid mimic of gonadotropin-releasing hormone, or GnRH. In a 2026 fertility paper, researchers asked whether adding this peptide to human chorionic gonadotropin (hCG) at the final egg-maturation step would improve outcomes for women with diminished ovarian reserve. [1, 2]

Eighty women with a poor ovarian response entered the single-blind randomized study. They were undergoing fertility care that included intracytoplasmic sperm injection, in which a sperm cell is introduced into a retrieved egg. Both groups had the same type of hCG trigger. One group also received triptorelin acetate. The comparison therefore estimates what adding triptorelin did in this particular hCG-containing protocol and selected group. It leaves the effect of triptorelin by itself an open question. [1]

The combination group had more eggs collected, more mature eggs, and more embryos judged good quality under the study's criteria. The investigators also reported a higher implantation rate. The primary outcome was clinical pregnancy, for which they detected no statistically clear difference. Miscarriage rates also had no clear separation. With 80 participants, the trial has limited ability to distinguish modest differences in clinical pregnancy or infrequent outcomes. An increase in the number of mature eggs is a finding about an earlier step and does not establish a change in live births. [1]

A brief pituitary response in this fertility setting and the hormone suppression seen with sustained-release triptorelin involve different exposure patterns. The fertility study used a specific acetate preparation and studied an investigational comparison. The U.S. Trelstar and Triptodur labels apply to their own formulations and indicate advanced prostate cancer and central precocious puberty, respectively. [1, 2, 3]

## Sources

1. Zamaniyan M et al. Effect of dual trigger on pregnancy outcomes in women with diminished ovarian reserve: A single-blind randomized clinical trial. International Journal of Reproductive BioMedicine (publication 2026-06-02). <https://pubmed.ncbi.nlm.nih.gov/42312114/>
2. Verity Pharmaceuticals Inc. TRELSTAR (triptorelin pamoate for injectable suspension), for intramuscular use. DailyMed (label effective 2026-06-30). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1b84d62-a369-a4b7-5c41-dd1f553a18f3>
3. Azurity Pharmaceuticals, Inc. TRIPTODUR (triptorelin) for extended-release injectable suspension, for intramuscular use. DailyMed (label updated 2025-09-14). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f41380e7-b830-432d-a5f5-a872932f107e>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 081 - Triptorelin GnRH.docx; article 401; content SHA-256 cbcc5a4f724a12974eb49f6e9d024e02bbf22a3d967149bfbebfde1b5c4f796a.
